138 related articles for article (PubMed ID: 30532024)
1. Transcriptome and protein interaction profiling in cancer cells with mutations in histone H3.3.
Lim J; Park JH; Baude A; Fellenberg J; Zustin J; Haller F; Krücken I; Kang HG; Park YJ; Plass C; Lindroth AM
Sci Data; 2018 Dec; 5():180283. PubMed ID: 30532024
[TBL] [Abstract][Full Text] [Related]
2. The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing.
Lim J; Park JH; Baude A; Yoo Y; Lee YK; Schmidt CR; Park JB; Fellenberg J; Zustin J; Haller F; Krücken I; Kang HG; Park YJ; Plass C; Lindroth AM
Sci Rep; 2017 Oct; 7(1):13459. PubMed ID: 29044188
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
[TBL] [Abstract][Full Text] [Related]
4. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
Amary F; Berisha F; Ye H; Gupta M; Gutteridge A; Baumhoer D; Gibbons R; Tirabosco R; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000
[TBL] [Abstract][Full Text] [Related]
5. Significance of Histone H3.3 (G34W)-Mutant Protein in Pathological Diagnosis of Giant Cell Tumor of Bone.
Miskad UA; Syamsul F; Dahlan H; Sungowati NK; Achmad D; Johan MP
Asian Pac J Cancer Prev; 2023 May; 24(5):1737-1741. PubMed ID: 37247296
[TBL] [Abstract][Full Text] [Related]
6. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
7. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
8. [DNA sequencing of H3F3A mutations in H3.3 immunohistochemistry-negative giant cell tumors of bone].
Gong LH; Zhang W; Sun XQ; Zhang M; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):190-193. PubMed ID: 33677880
[No Abstract] [Full Text] [Related]
9. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells.
Fellenberg J; Sähr H; Mancarella D; Plass C; Lindroth AM; Westhauser F; Lehner B; Ewerbeck V
Cancer Lett; 2019 Apr; 448():61-69. PubMed ID: 30742944
[TBL] [Abstract][Full Text] [Related]
10. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
Lutsik P; Baude A; Mancarella D; Öz S; Kühn A; Toth R; Hey J; Toprak UH; Lim J; Nguyen VH; Jiang C; Mayakonda A; Hartmann M; Rosemann F; Breuer K; Vonficht D; Grünschläger F; Lee S; Schuhmacher MK; Kusevic D; Jauch A; Weichenhan D; Zustin J; Schlesner M; Haas S; Park JH; Park YJ; Oppermann U; Jeltsch A; Haller F; Fellenberg J; Lindroth AM; Plass C
Nat Commun; 2020 Oct; 11(1):5414. PubMed ID: 33110075
[TBL] [Abstract][Full Text] [Related]
11. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
[TBL] [Abstract][Full Text] [Related]
12. Histone H3.3 G34 Mutations Alter Histone H3K36 and H3K27 Methylation In Cis.
Shi L; Shi J; Shi X; Li W; Wen H
J Mol Biol; 2018 May; 430(11):1562-1565. PubMed ID: 29689253
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Utility of Genetic and Immunohistochemical
Wągrodzki M; Tysarowski A; Seliga K; Wojnowska A; Stepaniuk M; Castañeda Wysocka P; Makuła D; Pieńkowski A; Szostakowski B; Zub R; Rutkowski P
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055156
[TBL] [Abstract][Full Text] [Related]
14. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
15. Reliability and Role of Mutation-specific H3F3A (Histone 3-3) G34W Immunohistochemistry to Differentiate Giant Cell Tumor of Bone From its Clinicoradiologic and Histologic Mimics: An Institutional Study.
Pasricha S; Pruthi M; Jajodia A; Kumar A; Gupta G; Sharma A; Tiwari A; Rohela H; Durga G; Kamboj M; Koyyala VPB; Mehta A
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):36-41. PubMed ID: 34347625
[TBL] [Abstract][Full Text] [Related]
16. Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone.
Ogura K; Hosoda F; Nakamura H; Hama N; Totoki Y; Yoshida A; Ohashi S; Rokutan H; Takai E; Yachida S; Kawai A; Tanaka S; Shibata T
Genes Chromosomes Cancer; 2017 Oct; 56(10):711-718. PubMed ID: 28545165
[TBL] [Abstract][Full Text] [Related]
17. Symplastic/pseudoanaplastic giant cell tumor of the bone.
Sarungbam J; Agaram N; Hwang S; Lu C; Wang L; Healey J; Hameed M
Skeletal Radiol; 2016 Jul; 45(7):929-35. PubMed ID: 27020452
[TBL] [Abstract][Full Text] [Related]
18. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
19. Recurrent H3.3 alterations in childhood tumors.
Lindroth AM; Plass C
Nat Genet; 2013 Dec; 45(12):1413-4. PubMed ID: 24270444
[TBL] [Abstract][Full Text] [Related]
20. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]